IS4094A - Aðferð til framleiðslu á fjölmorfuðu kristölluðu formi finasteríðs - Google Patents

Aðferð til framleiðslu á fjölmorfuðu kristölluðu formi finasteríðs

Info

Publication number
IS4094A
IS4094A IS4094A IS4094A IS4094A IS 4094 A IS4094 A IS 4094A IS 4094 A IS4094 A IS 4094A IS 4094 A IS4094 A IS 4094A IS 4094 A IS4094 A IS 4094A
Authority
IS
Iceland
Prior art keywords
finasteride
magnesium halide
polysomorphic
preparation
disclosed
Prior art date
Application number
IS4094A
Other languages
English (en)
Other versions
IS1671B (is
Inventor
H. Dolling Ulf
A. Mccauley James
J. Varsolona Richard
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26681536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS4094(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of IS4094A publication Critical patent/IS4094A/is
Publication of IS1671B publication Critical patent/IS1671B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/003Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J73/00Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04NPICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N5/00Details of television systems
    • H04N5/74Projection arrangements for image reproduction, e.g. using eidophor
    • H04N5/7416Projection arrangements for image reproduction, e.g. using eidophor involving the use of a spatial light modulator, e.g. a light valve, controlled by a video signal
    • H04N5/7458Projection arrangements for image reproduction, e.g. using eidophor involving the use of a spatial light modulator, e.g. a light valve, controlled by a video signal the modulator being an array of deformable mirrors, e.g. digital micromirror device [DMD]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Multimedia (AREA)
  • Signal Processing (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Seasonings (AREA)
  • Confectionery (AREA)
  • Dental Preparations (AREA)
IS4094A 1992-11-19 1993-11-16 Aðferð til framleiðslu á fjölmorfuðu kristölluðu formi finasteríðs IS1671B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97853592A 1992-11-19 1992-11-19
US08/010,734 US5468860A (en) 1992-11-19 1993-01-29 New finasteride processes

Publications (2)

Publication Number Publication Date
IS4094A true IS4094A (is) 1994-05-20
IS1671B IS1671B (is) 1997-12-19

Family

ID=26681536

Family Applications (2)

Application Number Title Priority Date Filing Date
IS4286A IS1692B (is) 1992-11-19 1993-11-05 Nýjar aðferðir til framleiðslu á finasteríð efnum
IS4094A IS1671B (is) 1992-11-19 1993-11-16 Aðferð til framleiðslu á fjölmorfuðu kristölluðu formi finasteríðs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS4286A IS1692B (is) 1992-11-19 1993-11-05 Nýjar aðferðir til framleiðslu á finasteríð efnum

Country Status (33)

Country Link
US (3) US5468860A (is)
EP (3) EP0599376B2 (is)
JP (2) JPH07110875B2 (is)
CN (1) CN1058018C (is)
AT (2) ATE164850T1 (is)
AU (1) AU658774B2 (is)
BG (2) BG62362B1 (is)
CA (1) CA2103107C (is)
CY (1) CY2135B1 (is)
CZ (3) CZ301160B6 (is)
DE (4) DE69317856T2 (is)
DK (2) DK0655458T3 (is)
DZ (1) DZ1733A1 (is)
ES (2) ES2072848T3 (is)
FI (4) FI107450B (is)
GR (4) GR940300045T1 (is)
HK (1) HK1008338A1 (is)
HR (2) HRP931410B1 (is)
HU (2) HU216195B (is)
IL (1) IL107574A (is)
IS (2) IS1692B (is)
LV (2) LV12212B (is)
MX (1) MX9307222A (is)
MY (2) MY110411A (is)
NO (3) NO305912B1 (is)
PH (1) PH31120A (is)
RO (2) RO115164B1 (is)
RU (1) RU2120445C1 (is)
SI (1) SI9300603B (is)
SK (2) SK281765B6 (is)
TW (1) TW257766B (is)
UA (1) UA41341C2 (is)
WO (1) WO1994011387A2 (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes
IT1270660B (it) * 1994-10-13 1997-05-07 Poli Ind Chimica Spa Procedimento microbiologico per la preparazione di 3-oxo-4-azasteroidi-17beta-carbossi sostituiti e uso dei prodotti come inibitori dell'enzima 5alfa-riduttasi
US5670643A (en) * 1995-03-16 1997-09-23 Glaxo Wellcome Inc. Method for preparing finasteride
US5585383A (en) * 1995-05-03 1996-12-17 Merck & Co., Inc. Process for crystallizing a 4-azasteroid 5alpha-reductase inhibitor
WO1997010217A1 (en) * 1995-09-15 1997-03-20 Merck & Co., Inc. 4-azasteroids for treatment of hyperandrogenic conditions
GB2338234B (en) * 1998-06-10 2000-05-03 Torcan Chemical Ltd Preparation of finasteride
ES2153789B1 (es) 1999-07-05 2001-10-16 Raga Consultores S L Procedimiento para la obtencion de 178-(n-terc-butlcarbamoil)-3-ona-4-aza-esteroides
WO2001032683A1 (en) * 1999-11-01 2001-05-10 Torcan Chemical Ltd. Production of polymorphic forms i and ii of finasteride by complexation with group i or ii metal salts
HUP0300937A3 (en) * 2000-09-07 2007-10-29 Reddys Lab Ltd Dr Novel polymorphic form of 17-betha-(n-ter. butyl carbamoyl)-4-aza-5alpha-androst-1-en-3-one and process for preparing it
EP1790653A3 (en) * 2000-09-07 2010-06-02 Dr. Reddy's Laboratories Ltd. Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it
MXPA03002031A (es) * 2000-09-07 2004-12-13 Reddys Lab Ltd Dr Forma polimorfica novedosa de 17-beta-(n-tercbutil carbamoil)-4-aza-5-alfa-androst-1-en-3-ona y proceso para preparar la misma.
KR100415858B1 (ko) * 2001-09-22 2004-01-24 한미약품 주식회사 17베타-(엔-3차-부틸카바모일)-3-온 스테로이드 화합물의제조방법
CN100428897C (zh) * 2002-08-16 2008-10-29 浙江寿峰堂生物工程有限公司 抗疲劳改善亚健康的保健食品及其制备方法
ES2206065B1 (es) * 2002-10-31 2005-08-16 Ragactives, S.L. Procedimiento para la obtencion de la forma polimorfica i de finasterida.
AU2003217439A1 (en) * 2003-03-19 2004-10-11 Hetero Drugs Limited Novel crystalline forms of finasteride
EP1651661B1 (en) * 2003-07-03 2008-08-27 Cipla Ltd. Process for the preparation of finasteride form i
US20050136015A1 (en) * 2003-12-17 2005-06-23 McKie Derrick B. Topical use of halosalicylic acid derivatives
US20070167477A1 (en) * 2006-01-13 2007-07-19 Mandava Venkata Naga Brahmeswa Processes to prepare finasteride polymorphs
US7531658B2 (en) * 2006-01-20 2009-05-12 Apotex Pharmachem Inc. Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones
US7687650B2 (en) 2006-02-03 2010-03-30 Jr Chem, Llc Chemical compositions and methods of making them
US7897800B2 (en) 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
AU2006337161B2 (en) 2006-02-03 2012-06-07 Obagi Cosmeceuticals Llc Anti-aging treatment using copper and zinc compositions
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
US20090076058A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched finasteride
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
EP2274609B1 (en) * 2008-05-05 2012-03-28 Abbott GmbH & Co. KG Method for evaluating the solubility of a crystalline substance in a polymer
CA2750636C (en) 2009-01-23 2017-07-25 Jr Chem, Llc Rosacea treatments and kits for performing them
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
EP0285383B1 (en) * 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
NZ225100A (en) 1987-06-29 1991-09-25 Merck & Co Inc Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates
US5084574A (en) * 1988-04-18 1992-01-28 Merck & Co., Inc. Dehydrogenation process
US5237061A (en) * 1988-10-31 1993-08-17 Merck & Co., Inc. Methods of synthesizing benign prostatic hypertropic agents and their intermediates
US5021575A (en) 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids
CA2044706C (en) * 1990-06-15 2003-02-25 Michael Midler Jr. Crystallization method to improve crystal structure and size
EP0462662A3 (en) * 1990-06-20 1992-08-19 Merck & Co. Inc. 17beta-n-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones
US5120847A (en) 1990-08-27 1992-06-09 Merck & Co., Inc. Process for iodinating or brominating the α-methylenic carbon of a secondary amide
US5091534A (en) 1990-08-27 1992-02-25 Merck & Co., Inc. Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids
US5061801A (en) * 1990-09-24 1991-10-29 Merck & Co., Inc. Intermediate for making 3-oxo-4-aza-androst-1-ene 17β-ketones
CA2050824A1 (en) * 1990-09-24 1992-03-25 John M. Williams Process for making 3-oxo-4-aza-androst-1-ene 17-.beta.-ketones
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes

Also Published As

Publication number Publication date
LV12212B (en) 1999-03-20
IS1692B (is) 1998-04-20
MY110411A (en) 1998-05-30
NO951986L (no) 1995-05-19
ES2052476T3 (es) 1998-06-16
HRP20000295B1 (en) 2002-08-31
CZ126895A3 (en) 1995-12-13
PH31120A (en) 1998-02-23
EP0599376A3 (en) 1994-09-28
BG103170A (en) 1999-09-30
SI9300603A (en) 1994-06-30
HU210535A9 (en) 1995-04-28
AU658774B2 (en) 1995-04-27
HRP931410A2 (en) 1996-06-30
FI20040559A (fi) 2004-04-21
LV12460B (en) 2000-09-20
ATE164850T1 (de) 1998-04-15
WO1994011387A2 (en) 1994-05-26
SI9300603B (sl) 2004-06-30
EP0655458A3 (en) 1996-07-10
FI114215B (fi) 2004-09-15
FI952422A0 (fi) 1995-05-18
HU216195B (hu) 1999-05-28
HU9303275D0 (en) 1994-03-28
GR950300043T1 (en) 1995-07-31
DK0655458T3 (da) 1999-09-27
IS4286A (is) 1994-05-20
DK0599376T4 (da) 2008-07-28
GR940300045T1 (en) 1994-07-29
FI952422A (fi) 1995-05-18
DE69317856D1 (de) 1998-05-14
NO951986D0 (no) 1995-05-19
WO1994011387A3 (en) 1994-09-29
NO990468L (no) 1995-05-19
SK65995A3 (en) 1995-10-11
AU5078793A (en) 1994-06-16
FI20010290A (fi) 2001-02-15
NO992580D0 (no) 1999-05-28
RU2120445C1 (ru) 1998-10-20
EP0599376B1 (en) 1998-04-08
RO115165B1 (ro) 1999-11-30
US5468860A (en) 1995-11-21
UA41341C2 (uk) 2001-09-17
NO307888B3 (no) 2000-06-13
IL107574A (en) 2000-07-16
ES2052476T1 (es) 1994-07-16
EP0599376B2 (en) 2008-04-16
FI114800B (fi) 2004-12-31
FI116941B (fi) 2006-04-13
CZ301191B6 (cs) 2009-12-02
MY110410A (en) 1998-05-30
CA2103107A1 (en) 1994-05-20
SK281765B6 (sk) 2001-07-10
NO307609B1 (no) 2000-05-02
HRP931410B1 (en) 2000-06-30
GR3029554T3 (en) 1999-06-30
CZ301160B6 (cs) 2009-11-18
CN1090583A (zh) 1994-08-10
EP0823436A2 (en) 1998-02-11
CA2103107C (en) 2010-09-28
CY2135B1 (en) 2002-05-21
DE655458T1 (de) 1995-11-30
DE69323754T2 (de) 1999-10-07
ES2072848T1 (es) 1995-08-01
NO992580L (no) 1995-05-19
TW257766B (is) 1995-09-21
JPH09235294A (ja) 1997-09-09
BG64464B1 (bg) 2005-03-31
DE69323754D1 (de) 1999-04-08
ES2072848T3 (es) 1999-05-01
MX9307222A (es) 1994-07-29
JP2742409B2 (ja) 1998-04-22
EP0655458B1 (en) 1999-03-03
JPH06199889A (ja) 1994-07-19
HUT66973A (en) 1995-01-30
NO307888B1 (no) 2000-06-13
DE69317856T2 (de) 1998-11-05
EP0823436A3 (en) 1998-11-25
DE599376T1 (de) 1994-12-08
NO305912B1 (no) 1999-08-16
US5652365A (en) 1997-07-29
SK286488B6 (sk) 2008-11-06
IL107574A0 (en) 1994-02-27
EP0655458A2 (en) 1995-05-31
CN1058018C (zh) 2000-11-01
DZ1733A1 (fr) 2002-02-17
IS1671B (is) 1997-12-19
EP0599376A2 (en) 1994-06-01
RO115164B1 (ro) 1999-11-30
JPH07110875B2 (ja) 1995-11-29
GR3026577T3 (en) 1998-07-31
US5886184A (en) 1999-03-23
HRP20000295A2 (en) 2000-08-31
ES2052476T5 (es) 2008-11-01
RU95112521A (ru) 1997-02-10
BG62362B1 (bg) 1999-09-30
LV12212A (lv) 1999-01-20
ATE177112T1 (de) 1999-03-15
HK1008338A1 (en) 1999-05-07
BG99637A (bg) 1996-04-30
FI20010289A (fi) 2001-02-15
FI107450B (fi) 2001-08-15
CZ287842B6 (en) 2001-02-14
LV12460A (lv) 2000-04-20
NO990468D0 (no) 1999-02-01

Similar Documents

Publication Publication Date Title
IS1671B (is) Aðferð til framleiðslu á fjölmorfuðu kristölluðu formi finasteríðs